Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Lilly now says it expects non-GAAP earnings from $23 to $23.70 a share this year, up from $21.75 to $23. The new guidance is ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q3 CY2025, with sales up 53.9% year on year to $17.6 billion.

Eli Lilly and Company said the partnership will result in the build of the most powerful supercomputer owned by a ...

Eli Lilly said on Wednesday it is partnering with Walmart to expand access to Lilly's weight-loss drug Zepbound, which will ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Now, let’s talk about the real contenders, okay. Let’s start with Eli Lilly, one I always said was going to get to trillion ...

Eli Lilly and Company has announced plans to invest more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Puerto Rico.

The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of ...